Cresset Asset Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Cresset Asset Management’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-8,896	Closed	-$259K	–	1132
2021 Q4	$259K	Buy	+8,896	New	+$270K	﹤0.01%	936
2019 Q2	–	Sell	-159	Closed	-$6K	–	1539
2019 Q1	$6K	Sell	159 -2	-1%	-$74	﹤0.01%	1316
2018 Q4	$5K	Buy	+161	New	+$6.92K	﹤0.01%	1038

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Cresset Asset Management's SUPN Position: Q1 2022 in Review

Cresset Asset Management sold out of Supernus Pharmaceuticals (SUPN) in Q1 2022, closing a stake of 8,896 shares — an estimated $259K sold.

Cresset Asset Management first reported a position in SUPN in Q4 2018 and held it in 3 quarters. The position peaked at $259K in Q4 2021. 230 funds tracked by Wall St. Rank hold SUPN as of Q1 2022.

Cresset Asset Management reported no remaining Supernus Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Cresset Asset Management sold 8,896 Supernus Pharmaceuticals shares in Q1 2022, an estimated $259K.
Cresset Asset Management first reported a position in Supernus Pharmaceuticals in Q4 2018 and held it in 3 quarters.
Cresset Asset Management's Supernus Pharmaceuticals position peaked at $259K in Q4 2021.
230 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2022.

Based on Cresset Asset Management's 13F filing for Q1 2022, filed 16 May 2022.